The chief government of pharmaceutical largesays his firm doesn’t have plans to take a position further in Russia, as that nation’s invasion of Ukraine is about to enter its third week.
Nonetheless, CEO Albert Bourla advised “Face the Nation” moderator Margaret Brennan that Pfizer shouldn’t be slicing ties with Russia fully, and famous that whereas the corporate makes “some medicines in Russia for Russia,” the corporate doesn’t export from Russia.
Bourla identified that commerce restrictions usually exempt lifesaving prescribed drugs for humanitarian causes.
“How can you say I’m not going to send the cancer medicines to Russians because of what they did,” Bourla stated.
Prior to now two weeks, a string of Western companies haveor withdrawn from Russian markets altogether. introduced this week they’d pull again.
Bourla additionally stated that the corporate’s publicity in Russia is restricted, and that any monetary fallout from the battle can be “very minimal” to Pfizer’s backside line. Lower than half a p.c of the corporate’s whole income comes from Russia, Bourla stated.
He advised Brennan that he doesn’t count on provide chain delays or any value strain to consequence from the battle.
“We are very independent in terms of our supplying our ingredients from those parts of the world,” Bourla stated. “We do not expect to see in the world any disruptions, right now at least, because of this war.”